“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...
pharmaphorum

Braveheart, AAVantgarde rounds head recent biofinancings

Our round-up of biotech financings is led this week by Braveheart Bio, a San Francisco biotech that has launched with $185 ...
Fierce Pharma

Biogen boosts sales outlook on 'resilient' legacy MS franchise as new launches build momentum

As momentum for Biogen’s newer drugs for neurological disorders builds at a slow and steady pace, it appears that the company can still count on its older products to hold down the fort and support | ...
StockStory.org on MSN

5 Insightful Analyst Questions From Biogen’s Q3 Earnings Call

Biogen’s third quarter results came in ahead of Wall Street’s revenue and profit expectations, driven by robust performance ...

Biogen tops quarterly profit estimates, eyes deals to build early-stage pipeline

Biogen beat Wall Street estimates for third-quarter profit, helped by better-than-expected sales of some of its multiple ...

Biogen Inc.: "LEQEMBI" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts ...